Skip to main content

    Main navigation

    • Investors
    • About
    • News
    • Contact us
    • Egoo.health
    • en
    • sv
Home

Main navigation

  • Investors
  • About
  • News
  • Contact us
  • Egoo.health
  • en
  • sv
 

Investors

+

Main navigation

Main navigation

  • News - Press releases
  • Financial Calendar
  • Financial reports
    • IPO and listning documents
  • Corporate governance
    • Articles Of Association
    • AGM and Extraordinary general meetings
      • Extraordinary Shareholders Meeting 19 November
      • Extraordinary general meeting January 2020
      • Annual General Meeting, May 20, 2020
    • Auditor
    • Election committee
    • Certified adviser
  • Share information
    • Major shareholders
    • Sharecapital
    • Incentive programme
    • Dividend Policy
    • Warrants (TO)
  • Board
  • Management
  • Insiders
  • IR Contact
  • Presentations

Management

Thomas Warthoe

Thomas Warthoe

CEO, CO-FOUNDER

Number of shares: 1 445 102
Warrants series TO1: 243 902

Entrepreneur with over 20 years of experience in the healthcare industry (and specifically diagnostics). Thomas has founded and developed three biotech companies. In two of the companies Thomas founded, Display System Biotech and Ampligon, successful exits were made. He has successfully entered strategic partnerships and licensing agreements with global diagnostic companies such as Backman Coulter, Shionogi Co and Omron Healthcare over the years.

Employed in Qlife Aps since founding 2018

Henrik Ljung

CFO Qlife Holding AB

CFO in Qlife Holding AB since June 2020.
Henrik has experience as CFO in listed companies, including Acconeer AB, Spectracure AB, Carbiotix AB, Lumito AB.
He has a Master of Business Administration and former Certified Public Accountant.

Peter Warthoe

Peter Warthoe

CSO, CO-FOUNDER

Number of shares: 1 201 200

Peter is an entrepreneur who has co-founded companies in life sciences, diagnostics and technology. Peter is a prominent scientist and has been quoted in a variety of scientific writings and has been mentioned more than a thousand times for his discovery of a gene profiling technique. Peter has made over 10 patent applications. Furthermore, he has an extensive network within and experience from negotiations with global medtech companies. Peter has the overall scientific responsibility for the company's products.

Employed in Qlife Aps since founding 2018

Ebbe Finding

Ebbe Finding

CTO, CO-FOUNDER

Number of shares: 296 400

Ebbe has extensive experience in mechanical engineering in areas such as medical and mobile devices for integrated electronics. Ebbe has been primarily responsible for developing the software in Egoo and the measuring instrument (measurement of absorbance, fluorescence and immunoturbidimetry). The software and the platform's ability to measure different types of analysis formats are the product's most important features.

Employed in Qlife Aps since founding 2018

Lars Bangsgaard

Lars Bangsgaard

CFO, CO-FOUNDER

Number of shares: 1 201 200

Lars has more than 25 years of experience in financial positions within Volvo Danmark, Rockwoll and Averhoff. Lars is a co-founder and has collaborated with other co-founders of previous companies with successful exits. Lars was previously an auditor and is responsible for the company's financial planning, reporting, calculations and budgets.

Employed in Qlife Aps since founding 2018

Qlife Management Group

Titel Name   Year  
CEO Thomas Warthoe HA/Bachelor Economics 2018  
CSO Peter Warthoe Cand. Scient. Molecular biology 2018  
CFO Lars Bangsgaard HD-R/Accounting 2018  
CTO Ebbe Finding Bachelor/Mechanical engineer 2018  

Qlife

Qlife Holding AB
Hamntorget 3
SE-252 21 Helsingborg, Sweden
info@egoo.health

Links

  • About
  • Investors
  • Egoo.health

Qlife’s vision is to facilitate regular blood biomarker testing from home environment. We aim to make blood sampling convenient, cheap, fast, accessible and accurate resulting in more frequent blood testing to gain insight into personal health, with increased possibility for earlier discovery of illnesses. Our product is an integrated platform consisting of a small home device, disposable capsules each a test for a specific biomarker, and a digital infrastructure that shares data with patient journal or hospital platform.